Last update 20 Jun 2024
Allogeneic EBV-specific anti-CD19 CAR-T cell therapy(Memorial Sloan-Kettering Cancer Center)
Last update 20 Jun 2024
Overview
Basic Info
Drug Type Universal CAR-T |
Synonyms- |
Target |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), EBV Protein inhibitors, Gene transference |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Acute Lymphoblastic Leukemia | Phase 1 | US | 01 Sep 2011 | |
| Chronic Lymphocytic Leukemia | Phase 1 | US | 01 Sep 2011 | |
| Lymphoma | Phase 1 | US | 01 Sep 2011 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free